Description

 Fine-needle aspiration (FNA) remains the gold standard for the diagnosis of thyroid cancer. However, currently a large number of FNA biopsies result in negative or undetermined diagnosis, which suggests better non-invasive tools are needed for the clinical management of thyroid cancer. Spectral-based quantitative ultrasound (QUS) characterizations may offer a better diagnostic management as previously demonstrated in mouse cancer models ex vivo. As a first step towards understanding the potential of QUS markers for thyroid disease management, this paper deals with the spectral-based QUS estimation of healthy human thyroids in vivo.